4//SEC Filing
COATS LONNEL 4
Accession 0001415889-24-027545
CIK 0001597264other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 4:47 PM ET
Size
18.3 KB
Accession
0001415889-24-027545
Insider Transaction Report
Form 4
COATS LONNEL
Director
Transactions
- Sale
Common Stock
2024-11-20$94.99/sh−213$20,233→ 12,066 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-20−7,500→ 0 totalExercise: $69.79Exp: 2028-06-21→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2024-11-20$69.79/sh+7,500$523,425→ 20,754 total - Exercise/Conversion
Common Stock
2024-11-20$76.24/sh+1,312$100,027→ 22,066 total - Sale
Common Stock
2024-11-20$93.15/sh−4,500$419,175→ 17,566 total - Sale
Common Stock
2024-11-20$94.24/sh−5,287$498,247→ 12,279 total - Sale
Common Stock
2024-11-21$94.87/sh−9,824$932,003→ 2,242 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-20−1,312→ 3,188 totalExercise: $76.24Exp: 2030-06-24→ Common Stock (1,312 underlying)
Footnotes (6)
- [F1]Effected pursuant to a trading plan adopted on August 21, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is an average price. The shares were sold in multiple transactions ranging from $92.71 to $93.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2).
- [F3]The price reported is an average price. The shares were sold in multiple transactions ranging from $93.74 to $94.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).
- [F4]The price reported is an average price. The shares were sold in multiple transactions ranging from $94.74 to $95.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4).
- [F5]This option was granted on June 21, 2018 and is fully vested as of the transaction date.
- [F6]This option was granted on June 24, 2020 and is fully vested as of the transaction date.
Documents
Issuer
Blueprint Medicines Corp
CIK 0001597264
Entity typeother
Related Parties
1- filerCIK 0001612528
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 4:47 PM ET
- Size
- 18.3 KB